The traditional six-month timeframe for defining platinum sensitivity is being challenged. A growing theory suggests that tumors progressing while on a PARP inhibitor have a distinct biology that responds poorly to subsequent platinum, indicating a potential need to move directly to therapies like ADCs.

The traditional definition of platinum-resistant ovarian cancer based on a six-month recurrence interval is becoming less rigid. Clinicians recognize this timeframe can be an arbitrary surrogate for tumor biology, influenced by imaging schedules. The paradigm is shifting, especially post-PARP inhibitor therapy, where the value of re-challenging with platinum is being reconsidered despite shorter intervals.

The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.

Clinicians should view HRD scores as a spectrum rather than a simple positive/negative result. For a patient with a score near the arbitrary cutoff and an excellent clinical response to platinum, oncologists may advocate for insurance coverage of PARP inhibitors.

Experts question the biological validity of the one-year cutoff for recurrence after adjuvant Aromatase Inhibitor (AI) therapy, a common clinical trial inclusion criterion. They suggest that clinical judgment should be applied, as the biological reality of resistance is not a binary switch at 12 months.

The term "platinum-resistant" is being replaced by "platinum-ineligible" because the traditional 6-month relapse cutoff is an arbitrary and poor predictor of treatment response. The new term more accurately identifies patients who progress during or immediately after platinum therapy, acknowledging that others may still benefit.

Achieving remission in ovarian cancer is common, but it's often not sustainable. The strategic use of maintenance therapies, like oral PARP inhibitors, is essential to prolonging the cancer-free period and is a central focus of modern treatment.

The clinical lexicon for recurrent ovarian cancer is evolving. The term "platinum resistant" is being replaced by "platinum ineligible." This reflects a more nuanced clinical judgment that platinum-based chemotherapy is not the best option for a patient's recurrence, rather than being based solely on a time-defined interval of relapse.

With multiple new effective options in platinum-resistant disease (relacorilant, pembrolizumab, ADCs), the key clinical question is shifting from choosing one superior drug to determining the optimal sequence. Biomarkers can guide initial choices, but sequencing multiple regimens, including re-using weekly paclitaxel backbones, is now a viable strategy.